Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Cambrex
Cambrex
Activities:
Ingredients
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
Therapeutic: ensifentrine for chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) comes in various guises, including chronic bronchitis and emphysema; and, although incurable, the symptoms can be managed with...
Merck’s clesrovimab meets all primary endpoints in Phase IIb/III trial for RSV in infants
A teaser of the Phase IIb/III trial released by Merck indicates that clesrovimab can reduce the need to medically attend lower respiratory infections caused by RSV in infants
Bringing biotech to the Baltics: the rise of Lithuania
Lithuania’s biotechnology competencies lie in cell and gene therapies, enzymes and the wider pharmaceutical industry, offering companies a rich pool of talent in a...
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Distribution
Cambrex expands stability storage capabilities with novel US facility
The facility allows for pharmaceutical and medical device storage at a wide range of temperatures and humidity levels, serving the US market with next day delivery
Manufacturing
Cambrex completes expansion at small molecule API facility
The company has announced it has doubled the size of its small molecule active pharmaceutical ingredient (API) manufacturing facility
Manufacturing
Cambrex completes Snapdragon Chemistry acquisition
The company continues to expand its portfolio of specialised solutions for pharmaceutical development and manufacturing
Manufacturing
Cambrex set to acquire Snapdragon Chemistry
“The acquisition of Snapdragon will accelerate our growth in the area of continuous flow process development and manufacturing"
Manufacturing
Cambrex invests in 21,000 sqft R&D facility in Minnesota
The facility is located on a 45-acre property and produces a wide range of APIs and pharmaceutical intermediates, including highly potent molecules and controlled substances
Manufacturing
Cambrex expands its stability storage business
Named Q1 Scientific, the service offers environmentally-controlled stability storage services to the pharmaceutical, medical device and life sciences industries
Manufacturing
Cambrex acquires leading EU stability storage company Q1 Scientific
Stability storage and testing is a critical component of drug development and commercialisation of new therapies
Subscribe now